Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

Status: Recruiting
DFCI Protocol ID: 17-481

This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers treated with a prior TRK inhibitor.

Conducting Institutions:

Massachusetts General Hospital, Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Anna Farago, MD, PhD, Massachusetts General Hospital

Site-responsible Investigators:

Steven Dubois MD, Dana Farber Cancer Institute


Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Key Inclusion Criteria:

  -  Advanced solid tumor for which, in the opinion of the Investigator, no other standard
     or investigational therapy offers greater benefit.

  -  A solid tumor diagnosis in the setting of:

       1. a documented NTRK fusion and a clinical history of relapse following a response
  to a prior TRK inhibitor

       2. a documented NTRK fusion unresponsive to a prior TRK inhibitor

       3. a documented NTRK fusion and a clinical history of intolerance to a prior TRK

  -  NTRK gene fusions will be identified via a CLIA certified (or equivalent) laboratory.
     Exception: Patients with Infantile Fibrosarcoma (IFS) and congenital mesoblastic
     nephroma (CMN) may be enrolled based on ETV6+ FISH test without identifying NTRK3

  -  Performance Status: Eastern Cooperative Oncology Group (ECOG) score ≤ 3 (age ≥16) or
     Lansky Performance Score (LPS) ≥40% (age<16). If enrolled with primary CNS tumor to be
     assessed by RANO, Karnofsky Performance Status (KPS) (age ≥16) or LPS (age<16) ≥ 50%

  -  Life expectancy > 4 weeks

  -  Adequate hematologic, hepatic and renal function.

  -  Patients with stable CNS primary tumor, brain metastases, or treated spinal cord
     compression are eligible if neurological symptoms and steroid use (if applicable) have
     been stable for 7 days prior to the first dose of LOXO-195

  -  Ability to receive study drug therapy by enteral administration

Key Exclusion Criteria:

  -  Required treatment with certain strong CYP3A4 inhibitors or inducers.

  -  Clinically significant active cardiovascular disease or history of myocardial
     infarction within 3 months prior to planned start of LOXO-195 or prolongation of the
     QT interval corrected (QTcF) > 480 msec within the past 6 months

  -  Major surgery within 7 days of enrollment

  -  Uncontrolled systemic bacterial, fungal or viral infection

  -  Pregnancy or lactation.

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.